NOCC Talks to Developer of New OVA1 Test
read more

Genentech Announces Positive Results of Avastin Phase III Study in Women... with Advanced Ovarian Cancer
First Phase III study of an anti-angiogenic therapy in advanced ovarian cancer to meet primary endpoint
read more

Regular Aspirin Use Lowers the Risk of Developing Ovarian Cancer
read more

Understand Your Risks for Ovarian Cancer
read more

Pelvic Symptoms May Not Mean Ovarian Cancer
read more

Combo Test Might Spot Ovarian Cancer Early
read more

Combo Test Might Spot Ovarian Cancer Early
read more

Researchers make progress on early detection of ovarian cancer
read more

Most Ashkenazi Jewish women should be tested for breast cancer genes, study finds
read more

Arrayit Corporation Announces Manufacturing Breakthrough
read more

Study Offers New Option for Women With Ovarian Cancer
read more

Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
read more

Possible Ovarian Cancer Treatment Target Identified
read more

Diet Rich in Soy May Lower Risk of Ovarian Cancer
read more

Report: US Cancer Cases, Deaths, Continue to Decline
read more

OU Research Could Give Hope in Cancer Fight
Compound is Being Tested That May Lead to Preventative Drug
read more

Pertuzumab plus Gemzar® Active in Platinum-resistant Ovarian Cancer
read more

Ovarian cancer still lacks reliable early diagnostic test
read more

Leukemia Drug May Help Some Ovarian Cancer Patients
read more

U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer
read more

Nanoparticles for gene therapy improve
read more

Court upholds right of scientists and patients to challenge gene patents
read more

AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
read more

Zeltia gets final EU okay for Yondelis drug
read more

Ovarian Cancer Drug Tested In San Antonio
read more

I Got Sick Then I Got Better
Theatre Review
read more

Partnership formed to detect ovarian cancer
read more

Researchers say rare metals can aid in fighting colon, ovarian cancer
read more

Color of hope: Teal ribbon shows support for women facing ovarian cancer
read more

New Ovarian Cancer Test Can Hone Referrals
read more

Walk In North Park Raises Ovarian Cancer Awareness
read more

The fight of her life
read more

The Enemy Within
NorthShore Magazine
read more

The FDA Rejects Another Good Cancer Drug
read more

Gene mutation is clue about cancer risks among Ashkenazi women
read more

Modified Chemo Regimen Effective in Advanced Ovarian Cancer
Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week.
read more

UPDATE 1, Nektar cancer drug shows promise in early trial
read more

Fertility Preservation Possible for Women with Ovarian Cancer
read more

Ovarian cancer walk raises $35,000
read more

Vermillion/Quest OVA1 Ovarian Cancer Risk Test Cleared by FDA
read more

New Research May Aid Earlier Detection Of Ovarian Cancer
read more

Blood test could improve survival in ovarian cancer patients
read more

New Treatment for Ovarian Cancer Looks Promising
read more

Join walk for ovarian cancer awareness
read more

Butterflies Released to Remember Ovarian Cancer Victims
read more

Hope Comes with Grant to Fight Ovarian Cancer
read more

Suicide Genes Help Slow Ovarian Tumor Growth in Mice
read more

Campaign For The Teal Ribbon
read more

Toward Earlier Detection of Ovarian Cancer
read more

Many Opt for Surgery to Lower Breast, Ovarian Cancer Risk
Women with BRCA gene mutations often choose preventive measures, study finds
read more

CAU and Georgia Tech collaborate to fight cancer
read more

Abbott, Fujirebio Co-Developing HE4/CA125 Dx to Improve Early Ovarian Cancer Detection
read more

Rare Ovarian Cancer Caused by One Genetic Mutation
read more

Low Ovarian Cancer Detection Rate by Symptoms Alone
Transvaginal ultrasound may be a more sensitive way to look for ovarian malignancy
read more

Symptoms absent in 80% of ovarian cancer patients
read more

Hormone Therapy Increases Odds of Ovarian Cancer
But risk remains low and decreases two years after stopping, study finds
read more

Menstrual Periods: Clues to Ovarian Cancer
Study Shows Risk of Death From Ovarian Cancer Linked to Overall Number of Ovulatory Cycles
read more

Does Race Affect Cancer Survival?
Breast Cancer Deaths Higher for Black Women Despite Equal Treatment
read more

Platypus Link to Ovarian Cancer
Researchers from the Royal Adelaide Hospital and University of Adelaide believe our oldest mammalian relative may help us to better understand ovarian cancer
read more

Holy Grail Of Cancer Research?
PARP Inhibitors May Ease Side Effects Of Chemotherapy
read more

New Cancer Drug Fights Tumors in Those With BRCA Mutations
Olaparib prevents malignant cells from repairing themselves, researchers say
read more

Ovarian Cancer Breakthrough Heralds New Era of Treatment
read more

Chickens are the only animals besides humans known to suffer from ovarian cancer
read more

Spare the Ovaries! What Women Should Ask Before a Hysterectomy
read more

Brave schoolgirl, eight, becomes youngest Briton to battle ovarian cancer
read more

Sharing Cancer Info May Be Empowering
Telling children about genetic risks fosters openness, expert says
read more

Early-Stage Ovarian Cancers Develop Less Aggressively
read more

Screening Tests Missing Early Signs of Ovarian Cancer
read more

Genetic Profile Found that Predicts Best Chemotherapy for Ovarian Cancers
read more

Addition Of Dasatinib To Standard Chemo Cocktail May Enhance Effect In Certain Ovarian Cancers
ScienceDaily (Apr. 25, 2009) - The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center. read more

Genetic Variations In MiRNA Processing Pathway And Binding Sites Help Predict Ovarian Cancer Risk
ScienceDaily (Apr. 23, 2009) - Genetic variations in the micro-RNA (miRNA) processing pathway genes and miRNA binding sites predict a woman’s risk for developing ovarian cancer and her prospects for survival, researchers from The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research. read more

Novogen's NV-128 Targets the MTOR Pathway to Block Differentiation And Induce Cell Death In Ovarian Cancer Stem Cells
(Apr. 21, 2009) - Data presented at the Annual Meeting of the American Association for Cancer Research in Denver has demonstrated that NV-128, a Novogen, Limited (ASX: NRT) (NASDAQ: NVGN) synthetic isoflavonoid compound, not only induces cell death in Ovarian Cancer Stem Cells (OCSCs), but also blocks their differentiation into structures which are required to support tumor growth. read more

Lpathomab®, Compelling New Preclinical Results - Ovarian Cancer
(Apr. 21, 2009) - Lpath, Inc. (OTCBB:LPTN), the category leader in bioactive-lipid-targeted therapeutics, reported compelling new in vivo and in vitro results relating to its preclinical drug candidate, Lpathomab, in various ovarian cancer studies. The results were presented today by Lpath scientists at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado. read more

Hysterectomy: Spare Ovaries, Boost Health?
Ovary Removal Decreases Ovarian Cancer Risk but Increases Risk of Heart Disease and Death, Study Says
(Apr. 21, 2009) -- Ovary removal during a hysterectomy is often done to reduce the risk of ovarian cancer. But doing so also boosts the risk of heart disease and death long-term, according to a new study. read more

Gene variations could predict ovarian cancer risk
Variations within women's genes could predict risk for ovarian cancer, a new study has found
(Apr. 20, 2009) - Researchers at the University of Texas M.D. Anderson Cancer Center report that women who had eight or more of these unfavorable variations, or genotypes, were 4.5 times more likely to develop ovarian cancer, and women with six to eight of the genotypes were at twice the risk. The findings are being reported at the 100th annual meeting of the American Association for Cancer Research. read more

Researchers at Melbourne's Peter MacCallum Cancer Centre have discovered a genetic key that could lead to world-first cure for ovarian cancer.
(Apr. 20, 2009) - A major Australain study is investigating whether gene mutations are responsible for the cancer, which claims the lives of 800 Australian women each year. read more

Chemo Combo Shows Promise Against Ovarian Cancer
HealthDay News (Apr. 19, 2009) -- Adding the drug dasatinib to a standard, two-drug chemotherapy regimen for treating ovarian cancer boosted the effectiveness of the drugs in laboratory tests, new research shows. read more

Some Radiation Therapy Treatments Can Decrease Fertility
ScienceDaily (Apr. 12, 2009) - In female cancer patients of reproductive age, radiation treatment directly to the ovaries should be avoided because there is a direct relationship between certain types of radiation therapy and fertility problems, according to a review in the April 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). read more

A mother's last wish: To see daughter wed
Volunteer organization helps cancer-stricken woman see dream wedding
(Apr. 9, 2009) - It’s a video wedding album that doesn’t leave a dry eye in the house - a mother giving away her daughter at a ceremony she might never had attended, at a financial cost she could never hope to meet. read more

Ovarian Cancer Screening Resulted in Many Unnecessary Surgeries
National Cancer Institute (Apr. 7, 2009) - Screening women for ovarian cancer often led to unnecessary surgeries and failed to detect the disease in its early stages, according to new results from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. The analysis focused on the 34,000 women in the NCI-sponsored trial who were screened annually for signs of ovarian cancer using transvaginal ultrasound and/or the CA-125 blood test. read more

Medicare Expands Coverage of Pet Scans as Cancer Diagnostic Tool
CMS' Coverage with Evidence Development Project Shows PET Scans as "Reasonable and Necessary" for Initial Treatment Decisions of Most Solid Tumor Cancers
(Apr. 6, 2009) - The Centers for Medicare & Medicaid Services (CMS) issued a final national coverage determination (NCD) to expand coverage for initial testing with positron emission tomography (PET) for Medicare beneficiaries who are diagnosed with and treated for most solid tumor cancers. read more

Yale Plans Closer Look at Exercise and Cancer
Studies will chart recovery of active women with breast or ovarian disease
HealthDay News  (Apr. 6, 2009) -- A Yale professor has received $7 million in federal grants for two studies into whether exercise affects ovarian and breast cancer recovery. read more

SNM Calls CMS PET Scan Decision a Major Benefit for Cancer Patients
National Oncologic PET Registry Provided Overwhelming Evidence of PET's Value
(Apr. 3, 2009) -SNM applauds today's decision by the Centers for Medicare and Medicaid Services (CMS) to expand coverage of positron emission tomography (PET) scans in the initial treatment strategy of patients with cancer. This decision was based, in large part, on compelling clinical evidence of the effectiveness of PET for cancer management and treatment contained in a comprehensive study known as the National Oncologic PET Registry (NOPR). read more

Catching Ovarian Cancer Early May Miss Aggressive Tumors
The finding casts the usefulness of screening into doubt, scientists say
HealthDay News  (Mar. 24, 2009) -- Early-stage ovarian cancers may be slower growing and less likely to spread than the more aggressive forms typically found in advanced stages of the disease, researchers report. read more

Morphotek ®, Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
PRNewswire (Mar. 23, 2009) - Morphotek ®, Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure. read more

Combo Screening Doesn't Spot Early Ovarian Cancer
Even finding it early may not save lives, researchers say
HealthDay News  (Mar. 20, 2009) -- A screening regimen that combines ultrasound and a blood test to detect CA125, a marker for ovarian cancer, fails to discover the cancer in its early stages and often results in unnecessary surgery, a new study shows. read more

Optimizing Chemotherapy with Bevacizumab for Ovarian Cancer
Information on Clinical Trial
read more